John P. Butler is CEO & President at Akebia Therapeutics, Inc. (AKBA). They have made 16 open-market trades across 3 companies since 2014, most recently 2026-08-06.
CIK 0001591467
5 open-market purchases totalling $571K since 2014, against 11 sales. Across 5 scored buys the stock is up 25.2% at ninety days, and 22.5 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AKBA | 3,718,564 | $2.5M |
| RLYP | 2,250 | $72K |
| KERX | 20,000 | $67K |
| ZYNE | 47,824 | $62K |
| Total | $2.7M |
Shares reported on the most recent Form 4, priced at the 2026-08-10 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 20% |
| Avg Move | +8.0% | +24.9% | +25.2% |
| Alpha | +10.2% | +24.2% | +22.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKBA | BUY | 2026-03-04 | 2026-03-05 | $1.25 | $87K | +20.7% | +7.3% | -21.3% |
| AKBA | SELL · 10b5-1 | 2026-02-02 | 2026-02-04 | $1.39 | $474K | -11.8% | -6.6% | +7.0% |
| AKBA | SELL · 10b5-1 | 2025-03-03 | 2025-03-04 | $1.83 | $170K | +24.2% | +3.3% | +78.6% |
| AKBA | SELL · 10b5-1 | 2025-02-03 | 2025-02-04 | $2.10 | $606K | -0.9% | -10.7% | +8.8% |
| AKBA | SELL | 2024-02-29 | 2024-03-01 | $1.58 | $147K | -20.3% | -7.9% | -39.0% |
| AKBA | SELL | 2024-02-27 | 2024-02-29 | $1.52 | $115K | -9.6% | +3.8% | -34.4% |
| AKBA | SELL | 2024-02-01 | 2024-02-02 | $1.68 | $156K | -7.3% | -1.8% | -21.2% |
| ZYNE | SELL | 2023-06-14 | 2023-06-15 | $0.35 | $40 | -5.8% | +0.0% | +280.0% |
| AKBA | SELL | 2023-03-01 | 2023-03-03 | $0.88 | $81K | -30.0% | -39.8% | +13.6% |
| AKBA | SELL | 2023-02-27 | 2023-03-01 | $0.81 | $31K | -12.2% | -34.8% | +11.5% |
| ZYNE | SELL | 2022-06-14 | 2022-06-16 | $1.01 | $54 | +8.5% | +3.8% | +8.5% |
| AKBA | SELL | 2022-02-28 | 2022-03-02 | $2.16 | $333K | -3.2% | -73.0% | -85.0% |
| AKBA | SELL | 2021-04-01 | 2021-04-01 | $3.40 | $14K | -7.3% | -5.4% | +12.8% |
| AKBA | SELL | 2021-03-01 | 2021-03-02 | $3.40 | $340K | +3.5% | -4.5% | -2.2% |
| AKBA | BUY | 2019-11-20 | 2019-11-21 | $3.44 | $172K | +69.5% | +86.7% | +173.7% |
| ZYNE | BUY | 2018-08-22 | 2018-08-22 | $6.43 | $32K | +26.9% | +32.3% | -24.5% |
| RLYP | SELL | 2016-06-07 | 2016-06-08 | $19.32 | $20K | -8.7% | +5.8% | N/A |
| RLYP | SELL · 10b5-1 | 2015-06-11 | 2015-06-15 | $34.62 | $38K | -30.6% | +0.6% | +0.6% |
| AKBA | BUY | 2014-12-29 | 2014-12-29 | $11.57 | $12K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-12-22 | 2014-12-22 | $11.92 | $12K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-12-15 | 2014-12-18 | $11.34 | $11K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-11-12 | 2014-11-13 | $10.31 | $10K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-03-25 | 2014-03-27 | $17.00 | $235K | -38.5% | -0.9% | -0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.